Susquehanna International Group’s NewAmsterdam Pharma NAMS Stock Holding History

Susquehanna International Group’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.97M	Buy	186,600 +68,300	+58%	+$2.22M	﹤0.01%	3939
2025 Q4	$4.15M	Buy	+118,300	New	+$4.31M	﹤0.01%	4325
2025 Q3	–	Sell	-13,100	Closed	-$237K	–	13374
2025 Q2	$237K	Buy	+13,100	New	+$239K	﹤0.01%	10869
2025 Q1	–	Sell	-54,300	Closed	-$1.4M	–	13110
2024 Q4	$1.4M	Buy	+54,300	New	+$1.15M	﹤0.01%	6130

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Susquehanna International Group's NAMS Position: Q1 2026 in Review

Susquehanna International Group reduced its NewAmsterdam Pharma (NAMS) stake by 91% in Q1 2026, selling an estimated $5.79M and leaving 17,825 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #9326.

Susquehanna International Group first reported a position in NAMS in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.86M in Q4 2025. 171 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

Susquehanna International Group held 17,825 shares of NewAmsterdam Pharma worth $571K as of Q1 2026.
Susquehanna International Group sold 177,810 NewAmsterdam Pharma shares in Q1 2026, an estimated $5.79M.
NewAmsterdam Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9326 holding.
Susquehanna International Group first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 6 quarters since.
Susquehanna International Group's NewAmsterdam Pharma position peaked at $6.86M in Q4 2025.
171 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.